HIV-Associated Diarrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, February 2012, Pages: 53

HIV-Associated Diarrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “HIV-Associated Diarrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global HIV-Associated Diarrhea Therapeutics market. The report identifies the key trends shaping and driving the global HIV-Associated Diarrhea Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global HIV-Associated Diarrhea Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the HIV-Associated Diarrhea Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) HIV-Associated Diarrhea Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries HIV-Associated Diarrhea Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the HIV-Associated Diarrhea Therapeutics market.
- Analysis of key recent licensing and partnership agreements in HIV-Associated Diarrhea Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HIV-Associated Diarrhea Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global HIV-Associated Diarrhea Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global HIV-Associated Diarrhea Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Human Immunodeficiency Virus (HIV) Associated Diarrhea - Introduction
2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.3.1 Infective Causes of Diarrhea
2.3.2 Non-Infective Causes of Diarrhea
2.4 Clinical Presentation/Symptoms
2.5 Diagnosis
2.6 Pathophysiology
2.7 Treatment
2.7.1 Pathogen-Specific Therapy
2.7.2 Symptomatic Treatment
2.8 GlobalData Pipeline Report Guidance
3 HIV-Associated Diarrhea Therapeutics - Market Characterization
3.1 Overview
3.2 HIV-Associated Diarrhea Therapeutics Market Size (2006 - 2011) - Global
3.3 HIV-Associated Diarrhea Therapeutics Market Forecast (2011 - 2019) - Global
3.4 HIV-Associated Diarrhea Therapeutics Market Size (2006 - 2011) - The US
3.5 HIV-Associated Diarrhea Therapeutics Market Forecast (2011 - 2019) - The US
3.6 HIV-Associated Diarrhea Therapeutics Market Size (2006 - 2011) - France
3.7 HIV-Associated Diarrhea Therapeutics Market Forecast (2011 - 2019) - France
3.8 HIV-Associated Diarrhea Therapeutics Market Size (2006 - 2011) - Germany
3.9 HIV-Associated Diarrhea Therapeutics Market Forecast (2011 - 2019) - Germany
3.10 HIV-Associated Diarrhea Therapeutics Market Size (2006 - 2011) - Italy
3.11 HIV-Associated Diarrhea Therapeutics Market Forecast (2011 - 2019) - Italy
3.12 HIV-Associated Diarrhea Therapeutics Market Size (2006 - 2011) - Spain
3.13 HIV-Associated Diarrhea Therapeutics Market Forecast (2011 - 2019) - Spain
3.14 HIV-Associated Diarrhea Therapeutics Market Size (2006 - 2011) - The UK
3.15 HIV-Associated Diarrhea Therapeutics Market Forecast (2011 - 2019) - The UK
3.16 HIV-Associated Diarrhea Therapeutics Market Size (2006 - 2011) - Japan
3.17 HIV-Associated Diarrhea Therapeutics Market Forecast (2011 - 2019) - Japan
3.18 Drivers and Barriers for the HIV-Associated Diarrhea Therapeutics Market
3.18.1 Drivers for the HIV-Associated Diarrhea Therapeutics Market
3.18.2 Barriers for the HIV-Associated Diarrhea Therapeutics Market
3.19 Opportunity and Unmet Need
3.20 Key Takeaway
4 HIV-Associated Diarrhea Therapeutics Market - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles of the Major Marketed Products in the HIV-Associated Diarrhea Therapeutics Market
4.3.1 Paromomycin (Humatin)
4.3.2 Trimethoprim-sulfamethoxazole (Septra)
4.3.3 Metronidazole (Flagyl)
4.3.4 Diphenoxylate/Atropine (Lomotil)
4.3.5 Loperamide (Imodium)
4.4 Key Takeaway
5 HIV-Associated Diarrhea Therapeutics Market - Pipeline Assessment
5.1 Overview
5.1.1 HIV-Associated Diarrhea Therapeutics - Regulatory Filing and Phase III Clinical Pipeline
5.1.2 HIV-Associated Diarrhea Therapeutics - Phase II Clinical Pipeline
5.2 HIV-Associated Diarrhea Therapeutics Market - Pipeline Assessment by Mechanism of Action
5.3 HIV-Associated Diarrhea Therapeutics Market - Technology Trends Analytical Framework
5.4 HIV-Associated Diarrhea Therapeutics Market - Pipeline Assessment by Clinical Phase of Development
5.5 HIV-Associated Diarrhea Therapeutics - Promising Drugs under Clinical Development
5.6 Molecule Profile for Promising Drugs under Clinical Development
5.6.1 Crofelemer
5.7 Key Takeaway
6 HIV-Associated Diarrhea Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country
6.2 Clinical Trials by Phase of Clinical Development
6.3 Clinical Trials by Trial Status
6.4 Prominent and Overall Sponsors
6.5 Brief Profiles of Top 10 Companies Participating in Clinical Trials
7 HIV-Associated Diarrhea Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 HIV-Associated Diarrhea Therapeutics - Future Players
8.1 Introduction
8.1.1 Napo Pharmaceuticals
9 HIV-Associated Diarrhea Therapeutics Market - Appendix
9.1 Market Definition
9.2 Abbreviations
9.3 Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Forecasting
9.3.4 Primary Research
9.3.5 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Bibliography

1.1 List of Tables
Table 1: HIV-Associated Diarrhea Therapeutics Market, Global, Revenues ($m), 2006 - 2011
Table 2: HIV-Associated Diarrhea Therapeutics Market, Global, Market Forecasts ($m), 2011 - 2019
Table 3: HIV-Associated Diarrhea Therapeutics Market, The US, Revenue ($m), 2006 - 2011
Table 4: HIV-Associated Diarrhea Therapeutics Market, The US, Market Forecasts ($m), 2011 - 2019
Table 5: HIV-Associated Diarrhea Therapeutics Market, France, Revenue ($m), 2006 - 2011
Table 6: HIV-Associated Diarrhea Therapeutics Market, France, Market Forecast ($m), 2011 - 2019
Table 7: HIV-Associated Diarrhea Therapeutics Market, Germany, Revenue ($m), 2006 - 2011
Table 8: HIV-Associated Diarrhea Therapeutics Market, Germany, Market Forecast ($m), 2011 - 2019
Table 9: HIV-Associated Diarrhea Therapeutics Market, Italy, Revenue ($m), 2006 - 2011
Table 10: HIV-Associated Diarrhea Therapeutics Market, Italy, Market Forecast ($m), 2011 - 2019
Table 11: HIV-Associated Diarrhea Therapeutics Market, Spain, Revenue ($m), 2006 - 2011
Table 12: HIV-Associated Diarrhea Therapeutics Market, Spain, Market Forecast ($m), 2011 - 2019
Table 13: HIV-Associated Diarrhea Therapeutics Market, The UK, Revenue ($m), 2006 - 2011
Table 14: HIV-Associated Diarrhea Therapeutics Market, The UK, Market Forecast ($m), 2011 - 2019
Table 15: HIV-Associated Diarrhea Therapeutics Market, Japan, Revenue ($m), 2006 - 2011
Table 16: HIV-Associated Diarrhea Therapeutics Market, Japan, Market Forecast ($m), 2011 - 2019
Table 17: HIV-Associated Diarrhea Therapeutics Market - Phase III Clinical Pipeline, 2011
Table 18: HIV-Associated Diarrhea Therapeutics Market - Phase II Clinical Pipeline, 2011
Table 19: HIV-Associated Diarrhea Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011
Table 20: HIV-Associated Diarrhea Therapeutics - Most Promising Drugs under Clinical Development, 2011
Table 21: HIV-Associated Diarrhea Therapeutics Market, Global, Clinical Trials, 2011
Table 22: HIV-Associated Diarrhea Therapeutics Market, Global, Clinical Trials by Phase, 2011
Table 23: HIV-Associated Diarrhea Therapeutics Market, Global, Clinical Trials by Status of Development, 2011
Table 24: HIV-Associated Diarrhea Therapeutics Market, Global, Sponsors, 2011
Table 25: HIV-Associated Diarrhea Therapeutics Market, Global, Companies by Phase, 2011

1.2 List of Figures
Figure 1: Approach to Acute Diarrhea in HIV-Positive Patients
Figure 2: HIV-Associated Diarrhea Therapeutics Market, Global, Revenues ($m), 2006 - 2011
Figure 3: HIV-Associated Diarrhea Therapeutics Market, Global, Market Forecast ($m), 2011 - 2019
Figure 4: HIV-Associated Diarrhea Therapeutics Market, The US, Revenue ($m), 2006 - 2011
Figure 5: HIV-Associated Diarrhea Therapeutics Market, The US, Market Forecasts ($m), 2011 - 2019
Figure 6: HIV-Associated Diarrhea Therapeutics Market, France, Revenue ($m), 2006 - 2011
Figure 7: HIV-Associated Diarrhea Therapeutics Market, France, Market Forecast ($m), 2011 - 2019
Figure 8: HIV-Associated Diarrhea Therapeutics Market, Germany, Revenue ($m), 2006 - 2011
Figure 9: HIV-Associated Diarrhea Therapeutics Market, Germany, Market Forecast ($m), 2011 - 2019
Figure 10: HIV-Associated Diarrhea Therapeutics Market, Italy, Revenue ($m), 2006 - 2011
Figure 11: HIV-Associated Diarrhea Therapeutics Market, Italy, Market Forecast ($m), 2011 - 2019
Figure 12: HIV-Associated Diarrhea Therapeutics Market, Spain, Revenue ($m), 2006 - 2011
Figure 13: HIV-Associated Diarrhea Therapeutics Market, Spain, Market Forecast ($m), 2011 - 2019
Figure 14: HIV-Associated Diarrhea Therapeutics Market, The UK, Revenue ($m), 2006 - 2011
Figure 15: HIV-Associated Diarrhea Therapeutics Market, The UK, Market Forecast ($m), 2011 - 2019
Figure 16: HIV-Associated Diarrhea Therapeutics Market, Japan, Revenue ($m), 2006 - 2011
Figure 17: HIV-Associated Diarrhea Therapeutics Market, Japan, Market Forecast ($m), 2011 - 2019
Figure 18: Opportunity and Unmet Need in the HIV-Associated Diarrhea Therapeutics Market - Antiprotozoal Treatment
Figure 19: Opportunity and Unmet Need in the HIV-Associated Diarrhea Therapeutics Market - Symptomatic Treatment
Figure 20: Strategic Competitor Assessment of the Marketed Products for HIV-Associated Diarrhea, 2011
Figure 21: Technology Trends Analytic Framework of the HIV-associated diarrhea Pipeline, 2011
Figure 22: Technology Trends Analytic Framework of the HIV-associated diarrhea Pipeline - Description, 2011
Figure 23: HIV-associated diarrhea Pipeline by Phase of Clinical Development, 2011
Figure 24: Mechanism Of Action: Crofelemer
Figure 25: HIV-Associated Diarrhea Therapeutics Market, Global, Clinical Trials by Phase, 2011
Figure 26: HIV-Associated Diarrhea Therapeutics Market, Global, Clinical Trials by Stage of Development, 2011
Figure 27: HIV-Associated Diarrhea Therapeutics Market, Global, Prominent Sponsors, 2011
Figure 28: HIV-Associated Diarrhea Therapeutics Market, Global, Overall Sponsors, 2011
Figure 29: HIV-Associated Diarrhea Therapeutics Market, Global, Companies by Phase, 2011
Figure 30: HIV-Associated Diarrhea Therapeutics Market, Drivers and Restraints, 2011
Figure 31: Implications for Future Market Competition in the HIV-Associated Diarrhea Therapeutics Market, 2011
Figure 32: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “HIV-Associated Diarrhea Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Human Immunodeficiency Virus (HIV) associated diarrhea therapeutics market. The report identifies the key trends shaping and driving the global HIV-associated diarrhea therapeutics market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on pipeline products within the global HIV-associated diarrhea therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The HIV-Associated Diarrhea Therapeutics Market is Forecast to Show Significant Growth Until 2019

GlobalData’s analysis suggests that the global Human Immunodeficiency Virus (HIV)-associated diarrhea therapeutics market was worth $499.1m in 2011. It is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.2% over the next eight years, to reach $935.5m by 2019. The global HIV-associated diarrhea therapeutics market will be driven by the launch of a new and efficacious treatment option which is in the late stage of development. The growth will be further augmented by the increasing incidence and associated factors.

HIV-Associated Diarrhea Therapeutics Market has Weak Competition between Few Generics

GlobalData analyzed the current competitive landscape for HIV-associated diarrhea drugs and found the competition to be weak. The HIV-associated diarrhea therapeutics market consists of antiprotozoal and anti-diarrheal drugs. Competition in the HIV-associated diarrhea therapeutics market is driven not only by product characteristics such as their efficacy and safety profile, but also by market characteristics such as the number of competitors, pricing and generics. The HIV-associated diarrhea therapeutics market is dominated by generic products which have medium to high efficacy and safety profiles. The current market does not contain any branded products. There is weak competition among the generic products. Another disadvantage associated with most of the current anti-diarrheal products is that they are absorbed into the blood and distributed throughout the body. This increases the risk of drug interaction with other drugs. These anti-diarrheal drugs slow down the flow of material through the intestine. This stops diarrhea but also increases the amount of time the toxin remains in the intestines, increasing the risk of infection for the patient. The risk is higher in HIV patients. The strong pipeline product will dominate the HIV-associated diarrhea therapeutics market in the future.

Napo Pharmaceuticals

Customers who bought this item also bought

• Diarrhea Global Clinical Trials Review, H1, 2013
• Diarrhea Global Clinical Trials Review, H1, 2012
• Global HIV Epidemiology and Patient Flow Analysis - 2012
• HIV/AIDS Therapeutics Market to 2018 - Despite Major Patent Expiries, Increased Uptake of Once-a-Day Fixed-dose Combination Drugs to Drive Growth
• Traveler's Diarrhea - Pipeline Review, H2 2012
• Antivirals Market to 2016 - Antiretroviral Agents and Combination Therapies to be Major Drivers HIV and Hepatitis C Markets
• Diarrhea - Pipeline Review, H2 2011
• Substance Abuse Therapeutics Market to 2018 - Effective Drug Therapies in the Treatment of Alcohol and Opioid Dependence Offer Significant Market Opportunities
• Diarrhea - Pipeline Review, H2 2012
• Phenylketonuria Therapeutics - Pipeline Assessment and Market Forecasts to 2019